{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"52.100","floor":"50.300"},"ipodate":{"start":"2020-10-28 00:00:00","end":"2020-11-02 00:00:00"},"minimumcapital":"26312.50","subscribed":"53.43","marketcap":"249.22億","H_marketcap":"55.68億","pe":"--","codesrate":"90.00","link":"https://staticpdf.iqdii.com/stockdata/notice/09995/2020/2020102800024_c.pdf","ipopricing":"52.100","resultdate":"2020-11-06 00:00:00","enddate":"2020-11-02 00:00:00","listeddate":"2020-11-09 00:00:00","issuenumber":"7653.70萬","issuenumberhK":"3061.50萬","issuenumberother":"4592.20萬","grayprice":"59.90","sponsors":"摩根士丹利亞洲有限公司,華泰金融控股(香港)有限公司,摩根大通證券(遠東)有限公司","raisemoney":"377660.00萬","use":"1、約50.0%，或243.65百萬美元（1,888.29百萬港元），將主要用于候選藥物的臨床開發及商業化；\n2、約25.0%，或121.82百萬美元（944.14百萬港元）將用于撥付建設新生產設施以擴大商業生產產能；\n3、約15.0%，或73.09百萬美元（566.49百萬港元）將用于償還榮昌制藥借款；\n4、約10.0%，或48.73百萬美元（377.66百萬港元）將用作一般企業及營運資金用途。","shares":500,"leadagent":"摩根士丹利亞洲有限公司,華泰金融控股(香港)有限公司,摩根大通證券(亞太)有限公司,瑞士銀行香港分行,中銀國際亞洲有限公司,交銀國際證券有限公司,海通國際證券有限公司,中泰國際證券有限公司","bookrunners":"摩根士丹利亞洲有限公司,華泰金融控股(香港)有限公司,摩根大通證券(亞太)有限公司,瑞士銀行香港分行,中銀國際亞洲有限公司,交銀國際證券有限公司,海通國際證券有限公司,中泰國際證券有限公司","coordinator":"摩根士丹利亞洲有限公司,華泰金融控股(香港)有限公司,摩根大通證券(亞太)有限公司,瑞士銀行香港分行","firstDayOpen":"60.60","IsEiio":0,"Interestdays":4,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"摩根士丹利亞洲有限公司","code":"E09995","name":"榮昌生物－Ｂ","fullname":"榮昌生物制藥(煙臺)股份有限公司"},"institutioninfo":{"principaloffice":"中國山東省自由貿易試驗區煙臺片區煙臺開發區北京中路58號","registrars":"香港中央證券登記有限公司","registrarstel":"(852) 2862 8628","chairman":"王威東","secretary":"李嘉,譚栢如","telephone":"(8653) 5611 3511","substantialshareholders":"榮達(21.4%),國投實體(7.38%)","principalactivities":"公司是一家正在進入商業化階段的生物制藥公司，致力于發現、開發和商業化創新的、有特色的生物藥，用于治療中國乃至全球多種醫療需求未被滿足的自身免疫、腫瘤科和眼科疾病。","website":"http://www.remegen.com"},"managerinfo":[{"managername":"王威東","post":"董事長兼執行董事","rankno":1},{"managername":"房健民","post":"首席科學官、首席執行官兼執行董事","rankno":2},{"managername":"何如意","post":"臨床研究主管、首席醫學官兼執行董事","rankno":3}],"investorinfo":[{"institutionname":"Fidelity International","shareholding":"5,652,500.0","percentage":7.39,"ReleaseDate":"2021-05-09 00:00:00","relatedparty":"富達基金(香港)有限公司","subsidiary":["Fidelity International"],"InverstorType":"基金"},{"institutionname":"BlackRock Funds","shareholding":"2,975,000.0","percentage":3.89,"ReleaseDate":"2021-05-09 00:00:00","relatedparty":"BlackRock, Inc.","subsidiary":["BlackRock Funds"],"InverstorType":"基金"},{"institutionname":"Lake Bleu Prime Healthcare Master Fund Limited","shareholding":"2,975,000.0","percentage":3.89,"ReleaseDate":"2021-05-09 00:00:00","relatedparty":"清池資本(香港)有限公司","subsidiary":["Lake Bleu Prime Healthcare Master Fund Limited"],"InverstorType":"基金"},{"institutionname":"LAV Amber Limited","shareholding":"2,975,000.0","percentage":3.89,"ReleaseDate":"2021-05-09 00:00:00","relatedparty":"LAV Biosciences Fund V, L.P.","subsidiary":["LAV Prime Limited","LAV Amber Limited"],"InverstorType":"公司"}],"TotalShareholdingPercentage":44.21},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":10}